The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a alike https://iantsay894282.ouyawiki.com/1967486/retatrutide_vs_tirzepatide_a_comparative_analysis